Pyrrolopyrimidine derivatives useful for treating proliferative diseases

Details for Australian Patent Application No. 2005211493 (hide)

Owner Novartis AG

Inventors He, Handan; Esser, Thomas; Traxler, Peter; Caravatti, Giorgio

Agent Davies Collison Cave

Pub. Number AU-B-2005211493

PCT Pub. Number WO2005/075460

Priority 60/540,034 29.01.04 US

Filing date 28 January 2005

Wipo publication date 18 August 2005

Acceptance publication date 7 August 2008

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

3 August 2006 PCT application entered the National Phase

  PCT publication WO2005/075460 Priority application(s): WO2005/075460

7 August 2008 Application Accepted

  Published as AU-B-2005211493

4 September 2008 Corrigenda

  Applications Accepted - Name Index Under the name Novartis AG, Application No. 2005211493, under INID( 54), correct the title to Pyrrolo pyrimidine derivatives useful for treating proliferative diseases

4 December 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005211495-Alkylation process using a catalyst comprising a solid acid and a hydrogenation metal

2005211491-Pyrrolidine derivatives acting as CCR3-receptor antagonists